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Fondation Bergonie, 180 rue de Saint Genes, 33076 Bordeaux, France.
Summary From 1972 to 1976, 95 patients with clinical stages I-IIIA Hodgkin's disease were treated by
chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) before and after
extended field radiotherapy. The CVPP schedule gave: (1) a constant drug dosage for each patient
independent of body surface or weight; and (2) a total drug dosage dependent on haematological tolerance,
since the treatment was given for 21 days or until the leukocyte count dropped to 2 x 101-1. The drug
dosage per unit body surface (or 'dose density') significantly correlates with the drop in leukocyte count
(P<0.001) and the tumour regression at the end of the induction course (P=0.020). Disease-free survival is
significantly related to dose density (P=0.050) but not to dose intensity calculated on the duration of
treatment (P=0.240). However, after exclusion of three marginal recurrences due to border-line radiotherapy,
the dose intensity significantly correlates with the disease-free survival (P=0.031) and with the duration of
complete remission (r=0.870).
In chemotherapy, the impact of drug dose on tumour
response is well known (Frei & Canellos, 1986). Recently the
impact of the amount ofdrug delivered per unit time or dose
intensity has been analysed (Green et al., 1980). A dose-
effect relationship according to dose intensity has been
shown in animal experimentation and in human pathology,
especially in stage II breast cancer (Hryniuk & Levine, 1986;
Hryniuk et al., 1986), in advanced breast cancer (Hryniuk &
Bush, 1984; Hryniuk et al., 1986), in advanced ovarian
cancer (Levin & Hryniuk, 1986) and in Hodgkin's disease
(HD) (DeVita et al., 1987; Green et al., 1980). In the latter,
the efficiency of MOPP-therapy (six courses) in advanced
stage HD significantly correlates with the rate of delivery of
vincristine (Longo et al., 1980), a reduction of over 65% of
nitrogen mustard (Carde et al., 1983) and the suppression of
prednisone (British National Lymphoma Investigation,
1975). In our institute, early recurrences after radiotherapy
alone (Lagarde et al., 1971) led us in 1967 to introduce
chemotherapy with cyclophosphamide, vinblastine, procarba-
zine and prednisone (CVPP) (Lagarde et al., 1975; Hoerni et
al., 1980). Good tolerance (Chauvergne et al., 1973) led us in
1972 to treat all our patients with an induction course of
CVPP followed by extended field radiotherapy and by a
consolidation course of CVPP. We chose to analyse results
in patients with clinical stages I through to IIIA (Lagarde et
al., 1988). By analogy with the study of DeVita et al. (1987),
we now analyse these results according to dose intensity and
density calculated with Hryniuk's method (Hryniuk, 1987;
Hryniuk & Bush, 1984).
Patients and methods
From January 1972 to October 1976, 102 patients with
clinical stages I-1"A (IA,IB,IIA, IIB and IIIA) HD were
treated by brief and intensive chemotherapy associated with
extended field radiotherapy. The CVPP chemotherapy
(Figure 1) combined four drugs: cyclophosphamide, an intra-
venous injection of 200mg every other day; vinblastine, an
intravenous injection of 10mg per week; procarbazine, six
capsules of 50mg per day, after an initial increment of one
capsule a day over the first 6 days; prednisone, a daily
injection of 120mg per day for 3 days, then 80mg per day
for 3 days and 40mg per day for the last 3 days. Total drug
dosage depended on haematological tolerance, since the
treatment was stopped at the twenty-first day or as soon as
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the patient's leukocyte count dropped to 2 x 1091-1. Each
unit drug dosage was the same for all patients and not, as in
other schedules, dependent on body surface or weight.
However, drug dosages were reduced for patients over 70
years (two cases) and for children under 15 years (five cases):
thus, only 95 patients were eligible for the present study. On
the other hand, for patients with bulky tumours over 10cm
and with insufficient tumoral reduction (less than 75%), the
induction course was reinforced by another course of CVPP
(10 cases).
Radiotherapy immediately followed chemotherapy, and
the interval never exceeded 6 days. The total dose was 40Gy
in involved regions and 35 Gy in adjacent areas. This dose
was delivered at 2 Gy per day and for 5 days per week, over
a period of 4 weeks. Kaplan's technique (Kaplan, 1968) with
extended field irradiation was used. For the supra-
diaphragmatic mantle, the fields of the mediastinum were
delineated according to the residual lymph nodes remaining
after induction chemotherapy and not according to the
initial involvement. For the subdiaphragmatic area, the
'inverted Y' technique was used wherever there were patho-
logical lymphographic findings, but only the para-aortic area
up to L5-S1 was treated wherever there were normal films.
A rest period of one month was inserted between the end
of irradiation and the beginning of the consolidation course
of CVPP. No maintenance therapy was given. Thus, the
overall treatment was brief (3.5 months).
All patients were hospitalised during treatment. Surveil-
lance was clinical and especially haematological, with a
blood cell count every other day during chemotherapy and
weekly during irradiation. Haematological surveillance
during induction chemotherapy was used to calculate the
average leukocyte count every other day and to establish the
average curve representing leukocyte changes during the
induction course. The leukocyte count slightly increased
during irradiation (Eghbali et al., 1978), but chemotherapy
could not be repeated for four patients because of persistent
leukopaenia. Finally, consolidation chemotherapy was
followed by four severe but reversible bone marrow hypo-
plasia and one lethal aplasia.
Therapeutic outcome was judged at two points by clinical
and radiological restaging: the first after induction chemo-
therapy gave the clinical response according to criteria of the
WHO code or the equivalent (Chauvergne et al., 1974); the
other just before consolidation chemotherapy gave the over-
all rate of complete remission (CR), since all patients with
partial remission at this time relapsed despite the consoli-
dation course. Finally, post-therapeutic surveillance was
carried out every half-year for 5 years, then every year for 5
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Figure 1 The CVPP schedule: standard density was calculated from unit dosage for a body surface of 1.5M2; standard intensity
was calculated from total dosage for a body surface of 1.5m2 over 3 weeks.
more years and then every other year to give the duration of
CR.
All data were collected in June 1987. The median follow-
up time is 13 years. Duration of CR was calculated from the
first day of treatment. The curves of disease-free survival
(DFS) were established according to the Kaplan-Meier
method (Kaplan & Meier, 1958).
Prognostic significance by comparison of DFS curves was
evaluated according to the log-rank test (Peto et al., 1977).
Significance of the correlation between two factors was
evaluated according to the non-parametric Kendall test or a
statistical regression analysis. Dose intensity and density
were calculated from total and unit dosages given by the
CVPP schedule. v '
From the total drug dosage, Hryniuk defines the dose
intensity (Hryniuk, 1987; Hryniuk & Bush, 1984). For each
drug, the dose intensity is the drug dose in milligrams per
square metre per week. In the CVPP schedule, dose intensity
was calculated over 3 weeks for the study of one course,
induction or consolidation, and over 3.5 months for all
treatment, induction plus consolidation courses. As in many
current chemotherapies, the total dosage of each drug in the
CVPP schedule was adapted to each patient's haematological
tolerance. It was thus possible to calculate the relative dose
intensity of each drug in each patient, and the average
relative dose intensity of all the four drugs.
The dose density was defined for each drug as the dose in
milligrams given per square metre of body surface. Unlike
many current chemotherapies, the dosage of each drug in the
CVPP schedule was not adapted to each patient's body
surface or weight. As with intensity, it was thus possible to
calculate the relative dose density of each drug in each
patient and the average relative dose density. In fact,
whatever the drug, dose density was always in inverse ratio
to body surface or weight.
To compare the results of different schedules of a regimen,
Hryniuk refers the relative dose intensity of each schedule to
a standard reference schedule (Hryniuk, 1987; Hryniuk &
Bush, 1984). This principle cannot be applied to the CVPP
regimen, which was used with different schedules but for
different patients at an advanced stage (Bloomfield et al.,
1976; Diggs et al., 1977; Morgenfield et al., 1979). However,
by analogy with this principle and to compare the results of
each patient treated by our CVPP schedule, we referred the
relative dose intensity and density to a standard reference
patient. Hryniuk assumes that whenever total or unit drug
dosage is not related to body surface area it must be referred
to a standard reference patient with a body surface of 1.5m2
and a weight of 60kg (Hryniuk & Bush, 1984). Figure 1
gives the standard dose density and intensity calculated over
3 weeks for each drug. We now always use the terms dose
density and intensity instead of average relative dose density
and intensity.
Results
In the CVPP schedule, the treatment was stopped at the
twenty-first day, or as soon as the patient's leukocyte count
dropped to 2 x 1091 1. The average curve representing leuko-
cyte changes during the induction course (Figure 2) consisted
of an initial plateau and a slope characterised by the
inflexion point and the gradient. This curve was perfectly
representative for all the 95 patients until the thirteenth day,
which was the minimal duration of the induction course.
This duration correlated with the leukocyte count at the
beginning of treatment (P=0.003), which governed the
height of the plateau and dose density (P<0.001), which in
turn governed the slope. Indeed, the dose density correlated
with the inflexion point (P=0.033) and the gradient
(P<0.001). A comparison between the leukocyte changes of
the two groups defined from the median dose density
(Figure 3) shows that the denser the treatment, the earlier
and steeper the slope. Finally, there was a 'leukocyte effect-
dose' relationship since the slope of the curve depended on
the dose density.
The search for a 'therapeutic effect-dose' relationship
poses the problem of measuring appropriate criteria. TheINFLUENCE OF DOSE INTENSITY AND DENSITY 647
first restaging after a short follow-up time (3 weeks) showed
that CR was achieved only for patients with a small tumoral
mass: 18 patients with tumoral diameter under 5cm were
considered in CR at day 21 of treatment. This explains why
dose density correlates with clinical short-term response only
for the 48 patients with tumoral diameter under 5cm (dose
density P=0.020) and not for all 95 patients (0.388). The
second restaging with longer follow-up time showed that CR
was finally achieved for all patients, except one progression
disease (PD) and three partial remissions (PR) followed by
early relapse. These therapeutic failures occurred despite a
high dose density for the PD and despite the consolidation
course for the PR.
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Post-therapeutic surveillance with a long follow-up time
(median 13 years) shows that DFS was 84% at 10 and 15
years (Lagarde et al., 1988), since there was no recurrence
beyond 8 years. Prognostic analysis of DFS by log-rank test
gives significance to the following factors: contiguous extra-
nodal involvement (P=0.008), more than three involved sites
(P=0.01), signs of compression (P=0.02), clinical stage IIIA
(P=0.03), subdiaphragmatic stages I-II (P=0.04). No multi-
variate analysis was performed because of the small number
of patients. Figures 4 and 5 show DFS curves of the two
groups defined from the median dose density and intensity
respectively. Comparison of these curves shows prognostic
significance for dose density (P=0.050) but not for dose
intensity (P=0.240). However, after exclusion of three
marginal recurrences due to insufficient radiotherapy, the
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Figure 4 Disease-free survival for two groups defined from the
median dose density (= 1). The number in parentheses indicates
patients exposed to risk.
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Figure 2 Average curve representing leukocyte changes during
the induction course. The number in parentheses indicates
patients under treatment.
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Figure 5 Disease-free survival for two groups defined from the
median dose intensity (0.75). The number in parentheses indi-
cates patients exposed to risk.
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Figure 3 Leukocyte changes during the induction course for
two groups defined from the median dose density (= 1).
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Figure 6 Duration of complete remission before the recurrence
versus dose intensity. After exclusion of marginal recurrences,
r=0.87.
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comparison of DFS curves shows prognostic significance for
density (P=0.011) and intensity (P=0.031). Indeed, these
three patients with an initial pulmonary contiguous extension
(stage E) received mediastinal irradiation delineated
not by initial involvement but after reduction due to induc-
tion therapy. Thus, these three marginal recurrences were
due to borderline radiotherapy (Lagarde et al., 1988).
Finally, Figure 6 shows the site and- duration of CR before
the emergence of first recurrence versus dose intensity. After
exclusion of marginal recurrences, there is a discernible
significant relationship, since a regression analysis shows a
correlation coefficient of 0.87 calculated over eight
recurrences.
Discussion
The use of a set drug dosage for each patient in the CVPP
schedule allows us to look at the influence of dose per
square metre, which we refer to as 'dose density'. The dose
density significantly correlates with the degree of myelo-
suppression (P<0.001), tumour regression (P=0.020) and
DFS (P=0.050).
This retrospective series also makes it possible to study the
dose intensity of the treatment. In the CVPP schedule, the
dose intensity depends especially on the duration of treat-
ment, and so on the leukocyte changes under treatment.
Indeed, the duration of induction therapy correlates with the
initial leukocyte count (P=0.003) and dose density governs
the rate of fall of leukocyte count (P= <0.001).
In the CVPP schedule, the comparison of the DFS curves
shows a prognostic significance for dose density (P=0.050)
but not for dose intensity (P=0.240). On one hand, the
median dose density is equal to the density for a standard
patient. This supports Hryniuk's choice of a body surface of
1.5m2 and a weight of 60kg as a standard value. On the
other hand, our median dose intensity was 0.75 and this
justifies our use of the term 'intensive' for our CVPP
schedule.
One patient had progressive disease despite a high dose
density and intensity for the induction course. Three patients
in PR relapsed early despite the consolidation course. These
patients had a low dose density and intensity; but over and
above insufficient chemotherapy these three failures were due
to secondary chemoresistance. Carde et al. (1983) showed
that dose intensity calculated over six courses of MOPP and
especially for the first three courses correlates well with the
overall rate of CR for patients with advanced HD (particu-
larly in symptomatic patients). There is a much better
relationship when dose intensity is calculated from drug
doses actually received after reductions for toxicity and not
from projected doses.
The analysis of recurrences poses the problem of the
influence of radiotherapy and chemotherapy. Indeed, the
three marginal recurrences occurred despite a high dose
density and intensity, and were due to radiotherapy margins.
The other recurrences occurred with a low dose density and
intensity, except two late recurrences in patients with a high
intensity who also received re-induction chemotherapy. This
retrospective series highlights some of the problems asso-
ciated with the influence of radiotherapy, the few recurrences
and the difficulty of performing multivariate analysis with
small numbers. However, like other studies on dose intensity,
these results show a possible value in intensive chemotherapy
especially in patients with bad prognostic disease factors
(pathological type, stage), whereas bad prognostic patient
factors (age, performance status) exclude treatment because
of bad tolerance.
In summary, dose density correlates with short-term
effects. A high dose density improves the CR rate at the end
of the first course by reduction of the duration of treatment
necessary for CR. However, a high dose density increases the
toxic effect, and so reduces the dose intensity for the course.
Thus, the therapeutic aim is to find a good compromise
between the unit dosage and rhythm of treatment leading to
the best therapeutic effect/toxic effect ratio. Dose intensity
correlates with long-term effects. A high dose intensity
improves the overall rate and duration of CR by deferring or
preventing recurrence, especially when prognostic factors are
poor. Other retrospective and prospective studies according
to Hryniuk's recommendations (Hryniuk & Bush, 1985) are
needed to test the hypotheses generated by this analysis of
dose intensity and density.
This work was possible thanks to grants from the Comite Departe-
mental des Pyrenees Atlantiques de la Ligue Nationale Contre le
Cancer.
References
BLOOMFIELD, C.D., WEISS, R.B., FORTUNY, I., VOSIKA, G. &
KENNEDY, B.G. (1976). Combined chemotherapy with cyclo-
phosphamide, vinblastine, procarbazine and prednisone (CVPP)
for patients with advanced Hodgkin's disease. An alternative
program to MOPP. Cancer, 38, 42.
BRITISH NATIONAL LYMPHOMA INVESTIGATION (1975). Value of
prednisone in combination chemotherapy of stage IV Hodgkin's
disease. Br. Med. J., iii, 413.
CARDE, P., MAcKINTOSH, F.R. & ROSENBERG, S.A. (1983). A dose and
time response analysis of the treatment of Hodgkin's disease with
MOPP therapy. J. Clin. Oncol., 1, 146. CHAUVERGNE, J., HOERNI, B. & DURAND, M. (1974). Langage
commun dans l'expression des resultats therapeutiques en canc&r-
ologie. Bull. Cancer (Paris), 61, 235.
HAUVERGNE, J., HOERNI, B., HOERNI-SIMON, G., DURAND, M. &
LAGARDE, C. (1973). Chimiotherapie de la maladie de Hodgkin
associant procarbazine, vinblastine, cyclophosphamide et methyl-
prednisolone. Analyse d'une serie de 124 cures. Zeitschr.
Krebsforsch., 80, 179.
DEVITA, V.T., HUBBARD, S.M. & LONGO, D.L. (1987). The chemo-
therapy of lymphomas: looking back, moving forward. The
Richard and Hinda Rosenthal Foundation Award Lecture.
Cancer Res., 47, 5810.
DIGGS, C.H., WIERMICK, P.H., LEVI, J.A. & KVOLS, L.K. (1977).
Cyclophosphamide, vinblastine, procarbazine and prednisone
with CCNU and vinblastine maintenance of advanced Hodgkin's
disease. Cancer, 39, 1949.
EGHBALI, H., HOERNI-SIMON, G., DURAND, M., CHAUVERGNE, J.,
TOUCHARD, J. & HOERNI, B. (1978). Hodgkin's disease treated
by chemotherapy and large field irradiation. Hematologic effects.
Acta Radiol. Oncol., 17, 289.
FREI, E. & CANELLOS, G.P. (1986). Dose: a critical factor in cancer
chemotherapy. Am. J. Med., 69, 585.
GREEN, J.A., DAWSON, A.A. & FELL, L.F. (1980). Measurement of
drug dosage intensity in MVPP therapy in Hodgkin's disease. Br.
J. Clin. Pharmacol.. 9. 511.
HOERNI, B., EGHBALI, H., DURAND, M. and 6 others (1980).
Hodgkin's disease, clinical stages I and II. Results of radical
irradiation with or without chemotherapy. Acta Radiol. Oncol.,
19, 183.
HRYNIUK, W.M. (1987). Average relative dose intensity and the
impact on design of clinical trials. Semin. Oncol., 14, 65.
HRYNIUK, W.M. & BUSH, H. (1984). The importance of dose
intensity in chemotherapy of metastastic breast cancer. J. Clin.
Oncol., 2, 1281.
HRYNIUK, W.M. & BUSH, H. (1985), Letter to the editor. J. Clin.
Oncol., 3, 1046.
HRYNIUK, W.M. & LEVINE, M.N. (1986). Analysis of dose intensity
for adjuvant chemotherapy trials in stage II breast carcinoma. J.
Clin. Oncol., 4, 1162.
HRYNIUK, W.M., LEVINE, M.N. & LEVIN, L. (1986). Analysis of
dose intensity for chemotherapy in early (stage II) and advanced
breast carcinoma. N C I Monogr., 1, 87.INFLUENCE OF DOSE INTENSITY AND DENSITY 649
KAPLAN, E.L. & MEIER, P. (1958). Non parametric estimation from
incomplete observations. Proc. Am. Stat. Assoc., 53, 457.
KAPLAN, H.S. (1968). Clinical evaluation and radiotherapeutic
management of Hodgkin's disease and the malignant lympho-
mas. N. Engl. J. Med. 278, 892.
LAGARDE, C., CHAUVERGNE, J., DURAND, M., HOERNI, B.,
HOERNI-SIMON, G. & TOUCHARD, J. (1975). Interet d'une
chimiotherapie complementaire de la radiotherapie dans les
stades I et II de la maladie de Hodgkin. Bull. Cancer (Paris), 62,
1.
LAGARDE, C., TOUCHARD, J., CHAUVERGNE, J. & HOERNI, B.
(1971). Limites de la radiotherapie dans les formes reticulaires de
la maladie de Hodgkin. J. Radiol. Electrol., 52, 153.
LAGARDE, P., EGHBALI, H., BONICHON, F., DE MASCAREL, I.,
CHAUVERGNE, J. & HOERNI, B. (1988). Brief chemotherapy
associated with extended field radiotherapy in Hodgkin's disease.
Long-term results in a series of 102 patients with clinical stages
I-IIIA. Eur. J. Cancer, 24, 1191.
LEVIN, L. & HRYNIUK, W.M. (1986). Dose intensity analysis of
chemotherapy of advanced ovarian carcinoma. Proc. Am. Soc.
Clin. Oncol., 5, 112 (abstract).
LONGO, D.L., YOUNG, R.C., WESLEY, M. and 4 others (1980).
Twenty years of MOPP chemotherapy for Hodgkin's disease
with chemotherapy long term follow-up of MOPP treated
patients at NCI. Ann. Intern. Med., 92, 587.
MORGENFIELD, M., SOMOZA, N., MAGNASCO, J. and 11 others
(1979). Combined chemotherapy cyclophosphamide, vinblastine,
procarbazine and prednisone (CVPP) vs CVPP plus CCNU
(CCVPP) in Hodgkin's disease. Cancer, 43, 1579.
PETO, R., PIKE, M.C., ARMITAGE, P. and 7 others (1977). Design
and analysis of randomised clinical trials requiring prolonged
observation of each patient. II. Analysis and examples. Br. J.
Cancer, 35, 1.